FFO
ALGS icon

Fortitude Family Office’s Aligos Therapeutics ALGS Stock Holding History

Fortitude Family Office’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68
Closed -$505 – 2274
2026
Q1 		$505 Buy
+68
New +$516 ﹤0.01% 1727

Other funds holding ALGS

GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $334M AUM 26.48% 1-Year Est. Return

Fortitude Family Office's ALGS Position: Q2 2026 in Review

Fortitude Family Office sold out of Aligos Therapeutics (ALGS) in Q2 2026, closing a stake of 68 shares — an estimated $505 sold.

Fortitude Family Office first reported a position in ALGS in Q1 2026 and held it in 1 quarter. The position peaked at $505 in Q1 2026. 3 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Fortitude Family Office reported no remaining Aligos Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 68 Aligos Therapeutics shares in Q2 2026, an estimated $505.
  • Fortitude Family Office first reported a position in Aligos Therapeutics in Q1 2026 and held it in 1 quarter.
  • Fortitude Family Office's Aligos Therapeutics position peaked at $505 in Q1 2026.
  • 3 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.